<SEC-DOCUMENT>0001354457-20-000507.txt : 20200922
<SEC-HEADER>0001354457-20-000507.hdr.sgml : 20200922
<ACCEPTANCE-DATETIME>20200922092135
ACCESSION NUMBER:		0001354457-20-000507
CONFORMED SUBMISSION TYPE:	25-NSE
CONFIRMING COPY:	
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20200922
DATE AS OF CHANGE:		20200922

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Therapix Biosciences Ltd.
		CENTRAL INDEX KEY:			0001611746
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		25-NSE
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38041

	BUSINESS ADDRESS:	
		STREET 1:		16 ABBA HILLEL ROAD
		CITY:			RAMAT GAN
		STATE:			L3
		ZIP:			5250608
		BUSINESS PHONE:		972-3-6167055

	MAIL ADDRESS:	
		STREET 1:		16 ABBA HILLEL ROAD
		CITY:			RAMAT GAN
		STATE:			L3
		ZIP:			5250608

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			The Nasdaq Stock Market LLC
		CENTRAL INDEX KEY:			0001354457
		IRS NUMBER:				521165937
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		25-NSE

	BUSINESS ADDRESS:	
		STREET 1:		One Liberty Plaza
		CITY:			New York
		STATE:			NY
		ZIP:			10006
		BUSINESS PHONE:		301-978-4144

	MAIL ADDRESS:	
		STREET 1:		Office of General Counsel
		STREET 2:		805 King Farm Blvd.
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>25-NSE
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<notificationOfRemoval>

    <schemaVersion>X0203</schemaVersion>

    <exchange>
        <cik>0001354457</cik>
        <entityName>The Nasdaq Stock Market LLC</entityName>
    </exchange>

    <issuer>
        <cik>0001611746</cik>
        <entityName>Therapix Biosciences Ltd.</entityName>
        <fileNumber>001-38041</fileNumber>
        <address>
            <street1>5 Azrieli Center (Square Tower)</street1>
            <street2></street2>
            <city>Tel-Aviv</city>
            <stateOrCountryCode>L3</stateOrCountryCode>
            <stateOrCountry>ISRAEL</stateOrCountry>
            <zipCode>6702501</zipCode>
        </address>
        <telephoneNumber>972-3-6167055</telephoneNumber>
    </issuer>

    <descriptionClassSecurity>American Depositary Shares</descriptionClassSecurity>

    <ruleProvision>17 CFR 240.12d2-2(b)</ruleProvision>

    <signatureData>
        <signatureName>Aravind Menon</signatureName>
        <signatureTitle>Hearings Advisor</signatureTitle>
        <signatureDate>2020-09-22</signatureDate>
    </signatureData>
</notificationOfRemoval>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.25
<SEQUENCE>2
<FILENAME>trpxdelistreason.txt
<TEXT>
Delisting Determination, The Nasdaq Stock Market, LLC,
September 22, 2020,  Therapix Biosciences Ltd. The Nasdaq
Stock Market LLC (the Exchange) has determined to remove
from listing the common stock of Therapix Biosciences Ltd.
(the Company), effective at the opening of the trading
session on October 2, 2020.
Based on review of information provided by the Company, Nasdaq
Staff determined that the Company no longer qualified for listing
on the Exchange pursuant to Listing Rule Listing Rule 5550(b).
The Company was notified of the Staff determination
on November 19, 2019. The Company appealed the determination
to a Hearing Panel on November 26, 2019. On February 4,
2020, upon review of the information provided by the Company,
the Panel determined to grant the Company request to remain
listed in the Exchange subject to certain milestones.
After failing to meeting the Hearings Panel exception, on
June 30, 2020, the Hearings Panel issued a final decision denying
the Company continued listing and notified the Company that trading
in the Company securities would be suspended on July 2, 2020.
The Listing Council did not call the matter for review.
The Staff determination to delist the Company became final
on August 14, 2020.

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
